Cingulate

Cingulate EBIT per Employee

The EBIT per Employee of Cingulate (CING) as of Nov 11, 2026 is -1.41 M USD. In the previous year, EBIT per Employee was -1.04 M USD — a change of 34.80% (lower).

EBIT per Employee

-1.41 MUSD

YoY

34.80%

Last updated:

EBIT per Employee of Cingulate is 2025 -1.41 M USD. EBIT per Employee of Cingulate was 2024 -1.04 M USD. It decreases by 34.80% lower compared to the previous year.

The Cingulate EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-776,484.00 USD
Jan 1, 2020
-472,224.20 USD
Jan 1, 2021
-1.38 M USD
Jan 1, 2022
-1.17 M USD
Jan 1, 2023
-1.52 M USD
Jan 1, 2024
-1.04 M USD
Jan 1, 2025
-1.41 M USD
The Cingulate EBIT per Employee history
YEAREBIT per EmployeeYoY
-1.41 MUSD+34.80%
-1.04 MUSD-31.28%
-1.52 MUSD+30.08%
-1.17 MUSD-15.37%
-1.38 MUSD+191.94%
-472,224.20USD-39.18%
-776,484.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EBIT per Employee of Cingulate is -1.41 M USD in 2025.

EBIT per Employee of Cingulate changed from -1.04 M USD to -1.41 M USD, representing a 34.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Cingulate since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cingulate

All Key Metrics — Cingulate